Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. The knowledge of the mechanism of action of CD16a gave rise to several strategies to improve ADCC, by working on either the mAbs or the NK cell. In this review, we give an overview of CD16a biology and describe the latest strategies employed to improve antibody-dependent NK cell cytotoxicity.
CITATION STYLE
Coënon, L., & Villalba, M. (2022, June 3). From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2022.913215
Mendeley helps you to discover research relevant for your work.